Evidence map›Paper›PMID 32308993›Full record

ReviewInternational journal of Alzheimer's disease2020

Clinical Trials in Alzheimer's Disease: A Hurdle in the Path of Remedy.

Alexandra E Oxford, Erica S Stewart, Troy T Rohn

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of Alzheimer's disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 107 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Connectome-based biophysics models of Alzheimer's disease diagnosis and prognosis.Translational research : the journal of laboratory and clinical medicine · 2023
    Review
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Alexandra E OxfordDepartment of Biological Sciences, Boise State University, Science Building, Room 228, Boise, Idaho 83725, USA.ORCID https://orcid.org/0000-0002-8454-8852
Erica S StewartDepartment of Biological Sciences, Boise State University, Science Building, Room 228, Boise, Idaho 83725, USA.ORCID https://orcid.org/0000-0003-2872-226X
Troy T RohnDepartment of Biological Sciences, Boise State University, Science Building, Room 228, Boise, Idaho 83725, USA.ORCID https://orcid.org/0000-0002-8406-1956
Boise State University · US

Funding

Nuclear Localization of an Amino-Terminal Fragment of Apolipoprotein E4 in the Alzheimer's Disease BrainR15AG042781 · NIA · BOISE STATE UNIVERSITY · PI ROHN, TROY T · 2013 to 2022
$1.1M
NIA NIH HHS R15 AG042781
6 · The paper itself

Abstract

Human clinical trials seek to ameliorate the disease states and symptomatic progression of illnesses that, as of yet, are largely untreatable according to clinical standards. Ideally, clinical trials test "disease-modifying drugs," i.e., therapeutic agents that specifically modify pathological features or molecular bases of the disease and would presumably have a large impact on disease progression. In the case of Alzheimer's disease (AD), however, this approach appears to have stalled progress in the successful development of clinically useful therapies. For the last 25 years, clinical trials involving AD have centered on beta-amyloid (A

Identifiers

PMID32308993
PMCPMC7152954
OpenAlexW3014974762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.